ArticleFrontiers in human neuroscience2026
Association of remnant cholesterol with cognitive impairment: a cross-sectional study.
Article in Frontiers in human neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although dyslipidemia has been implicated in the development of cognitive impairment, the association between remnant cholesterol (RC) and cognitive outcomes remains incompletely understood. Methods: We conducted a cross-sectional study using data from 1,136 participants at Liuyang Jili Hospital from 2022. RC was calculated as total cholesterol minus low-density and high-density lipoprotein cholesterol, and cognitive function was assessed using the Mini-Mental State Examination. Restricted cubic spline and multivariable logistic regression models were used to evaluate associations between RC and cognitive impairment, with subgroup, and sensitivity analyses. Machine learning models with SHapley additive explanation (SHAP) values were applied to assess variable importance. Results: Participants had a median age of 68 years, and 21.2% had cognitive impairment. Higher RC levels were associated with increased risk of cognitive impairment (per 1-mmol/L increase: adjusted odds ratio, 3.47; 95% CI, 2.34-5.25; Conclusion: Elevated RC levels are positively associated with an increased risk of cognitive impairment. These findings suggest that remnant cholesterol may be an important and modifiable risk factor for cognitive dysfunction, warranting confirmation in prospective longitudinal studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.